GSK Just Wrote a $10.6 Billion Check for Two Drugs That Don't Exist Yet
GSK is spending $10.6 billion to buy Nuvalent and its two experimental lung cancer drugs, neither of which is approved yet. It's the company's biggest acquisition in over a decade, and it tells you everything about where Big Pharma thinks the money is headed.
The Biggest Bet GSK Has Made in Over a Decade
Imagine walking into a car dealership, pointing at two vehicles still on the assembly line, and wiring $10.6 billion on the spot. That's essentially what GSK just did.
The British pharma giant announced an all-cash deal to acquire Nuvalent, a Cambridge-based biotech focused on precision lung cancer therapies. At $124 per share, the offer represents a 40% premium to Nuvalent's last closing price. It's the second-largest acquisition GSK has ever made, trailing only the ~$20 billion 2014 Novartis asset swap.
And the two drugs at the center of this deal? Neither one is approved yet.
What GSK Is Actually Buying
Nuvalent's pipeline is built around two experimental therapies for non-small cell lung cancer (NSCLC), each targeting a specific genetic mutation that drives tumor growth. Think of these mutations as typos in your DNA's instruction manual; they tell cells to keep growing when they should stop.
The first drug is zidesamtinib, which targets a mutation called ROS1. The FDA has accepted its application, and a decision is expected by September 18, 2026. If approved, it could launch in the U.S. before year's end. In clinical trials, zidesamtinib showed an overall response rate of 44% in patients who had already failed other treatments. For patients with brain metastases (a common and devastating complication of lung cancer), intracranial response rates reached as high as 72.7%.
The second is neladalkib, which goes after ALK mutations. Nuvalent has already met with the FDA and plans to submit its application in the first half of 2026. A Phase 3 trial called ALKAZAR is also underway, testing neladalkib head-to-head against Roche's alectinib, the current gold standard for first-line ALK-positive lung cancer.
So GSK isn't buying two random science experiments. These are late-stage assets with clear regulatory timelines and shots at displacing established competitors.
The Patent Cliff Is Coming. GSK Knows It.
Every big pharma company lives in fear of the same thing: the moment their best-selling drugs lose patent protection and generic competitors flood in. GSK's clock is ticking, and the company has been on an acquisition spree to reload its pipeline before the cliff arrives.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Across 2025 and 2026, GSK has announced four acquisitions totaling roughly $14.7 billion. That includes IDRx, efimosfermin, 35Pharma (pulmonary hypertension, $950 million), and now Nuvalent. It's a spending spree that would make a newly single person's credit card company nervous.
But Nuvalent is the crown jewel. GSK expects the deal to boost sales and operating profit starting in 2027 and to become accretive to core earnings per share by 2029. The company says the acquisition supports its goal of reaching £40 billion in annual sales by 2031.
After accounting for cash on Nuvalent's balance sheet, GSK's net outlay is closer to $9.4 billion. The deal is funded through a mix of new debt, existing credit lines, and cash on hand. GSK insists it won't affect its credit rating, dividend, or financial guidance. (Every acquirer says that. We'll see.)
Why Lung Cancer, and Why Now?
Lung cancer isn't just any oncology market. It's the oncology market.
Global NSCLC therapeutics generated roughly $24–25 billion in 2025 and are projected to balloon to approximately $80 billion by 2035. Within that universe, ALK-positive and ROS1-positive cancers are relatively small patient populations (ALK is about 3–7% of NSCLC cases; ROS1 is only 1–2%). But these patients cycle through multiple lines of expensive targeted therapy, making the revenue per patient extraordinarily high.
The ALK market is the real prize. It's three to five times larger than ROS1, and a best-in-class ALK inhibitor could realistically generate $1–2 billion or more in annual sales if it can unseat alectinib and lorlatinib. That's blockbuster territory, the pharmaceutical equivalent of a franchise quarterback.
ROS1 is smaller but still meaningful: the market across major countries was around $300 million in 2024 and growing fast. A top ROS1 drug could reach $500 million to $1 billion annually, though it'll be splitting the pie with Bristol Myers Squibb's repotrectinib and Nuvation's taletrectinib.
GSK is essentially buying a two-for-one combo meal in the fastest-growing segment of the world's largest cancer market.
Wall Street Shrugged (Mostly)
Analyst reaction landed exactly where you'd expect for a signed, all-cash deal at a fixed price. Most firms downgraded Nuvalent to Hold or Neutral, with price targets converging right around the $124 offer. UBS cut its target from $138 to $124. Bernstein, Guggenheim: same story.
The consensus across 19 analysts settled at an average target of roughly $128, implying modest upside. When a cash acquisition is announced, there's just not much for analysts to debate; the stock becomes a bet on whether the deal closes, not on the science.
A few holdouts remain bullish on Nuvalent's standalone value. Leerink kept an Outperform rating with a $165 target. These are "what if the deal falls apart" prices, essentially arguing that Nuvalent's pipeline is worth more than $124 per share on its own.
One contrarian DCF analysis pegged Nuvalent's intrinsic value at just $61 per share, suggesting GSK is paying a hefty strategic premium. But that's the nature of pharma M&A: you're not buying today's revenue (Nuvalent has essentially none). You're buying tomorrow's franchise.
The Bigger Picture: GSK's Precision Oncology Pivot
Zoom out, and a pattern emerges. GSK has been methodically transforming itself from a diversified healthcare conglomerate into a focused biopharma company built around precision medicine.
The Haleon consumer health spinoff in 2022 was the starting gun. Since then, GSK has been stacking acquisitions in oncology (Sierra Oncology for myelofibrosis, IDRx for GI cancer), respiratory (Aiolos Bio, 35Pharma), and now targeted lung cancer. The strategy is clear: buy drugs aimed at well-defined patient populations with strong biomarkers, where clinical trials are smaller, faster, and more likely to succeed.
Nuvalent fits that playbook perfectly. ROS1 and ALK mutations are easy to test for, and the patients who have them respond dramatically to the right targeted therapy. It's the opposite of the old "spray and pray" approach to oncology.
What Could Go Wrong?
Plenty. Zidesamtinib still needs FDA approval. Neladalkib hasn't even filed its application yet. The ALKAZAR trial pitting neladalkib against alectinib will take years to read out, and there's no guarantee it wins. Competition in both ALK and ROS1 is fierce, with Roche, Pfizer, and Bristol Myers Squibb all defending their turf.
And $10.6 billion is a lot of money to pay for drugs that haven't generated a single dollar of commercial revenue. If either program stumbles, GSK will have overpaid for half a pipeline.
But if both drugs deliver? GSK could own the two most important targeted therapy franchises in lung cancer heading into the 2030s. For a company staring down a patent cliff, that's the kind of insurance policy worth writing a very large check for.
Clinical & Regulatory4 min read
Moderna's Flu Shot Just Cleared Its Biggest Hurdle Yet
Moderna's mRNA flu vaccine just got a unanimous thumbs-up from the FDA's advisory committee. If approved by August 5, it would be the first mRNA flu shot ever licensed in the U.S., opening a multibillion-dollar market that could redefine Moderna's future beyond COVID.
